ORBIMED ADVISORS LLC 13D and 13G filings for Kala Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-10-14 5:00 pm Sale |
2021-10-12 | 13G | Kala Pharmaceuticals, Inc. KALA |
ORBIMED ADVISORS LLC | 0 0.000% |
-188,568 (Position Closed) |
Filing |
| 2021-03-01 6:09 pm Unchanged |
2020-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA |
ORBIMED ADVISORS LLC | 188,568 8.410% |
0 (Unchanged) |
Filing |
| 2021-02-12 4:53 pm Purchase |
2020-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA |
ORBIMED ADVISORS LLC | 188,568 8.410% |
50,654 (+36.73%) |
Filing |